LOGIN  |  REGISTER
Cue Biopharma

RxSight to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences

August 22, 2024 | Last Trade: US$8.85 0.43 -4.63

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.

  • Morgan Stanley 22nd Annual Global Healthcare Conference
    - Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY
  • Wells Fargo 2024 Healthcare Conference
    - Fireside Chat: Thursday, September 5, 2024, at 3:45 p.m. ET in Boston, MA

Interested parties may access live and archived webcasts of these events at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page